Actuate Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Actuate Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage GSK-3 inhibitor play in hard-to-treat cancers; significant clinical and execution risk outweighs mechanism novelty; likely a binary event catalyst stock. Actuate is early-stage with minimal cash burn, a differentiated mechanism (GSK-3 inhibition), and multiple clinical programs; however, as a 12-person semi-virtual biotech without revenue, success depends entirely on.
What is Actuate Therapeutics, Inc.'s industry? Actuate Therapeutics, Inc. (actuatetherapeutics.com) operates in Oncology Drugs. AskCyborg classifies Actuate Therapeutics, Inc. under Oncology Drugs in its company registry.
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers through GSK-3 inhibition, with its lead product candidate elraglusib in Phase 2 trial for metastat...
Cyborg Score thesis
Early-stage GSK-3 inhibitor play in hard-to-treat cancers; significant clinical and execution risk outweighs mechanism novelty;...
Read the full analyst-debate transcript →Get the Latest Actuate Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeActuate Therapeutics, Inc. Overview
Pro stress-test →Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers through GSK-3 inhibition, with its lead product candidate elraglusib in Phase 2 trial for metastatic pancreatic ductal adenocarcinoma. The company operates as a semi-virtual biopharmaceutical organization with a lean footprint.
Strategic Profile
Pro stress-test →Actuate is executing multiple clinical trials including Phase 2 for myelofibrosis, Phase 1/2 for pediatric neuroblastoma, and Phase 2 for salivary gland carcinomas. The company's focus on GSK-3β inhibition targets multiple oncogenic pathways in drug-resistant cancers, positioning it in the competitive oncology therapeutics market where clinical-stage biotech programs targeting unmet needs in solid and hematologic malignancies command premium valuations pending trial outcomes.
Competitive Landscape
Pro stress-test →Actuate competes in the clinical-stage oncology therapeutics space against established immunotherapy platforms (checkpoint inhibitors, CAR-T cell therapies) and conventional chemotherapy regimens. Direct competitors include other GSK-3 pathway programs and multi-mechanism cancer platforms from better-capitalized clinical-stage and commercial biotech firms. Key differentiation hinges on elraglusib's ability to overcome chemotherapy resistance and enhance immune activation in patient populations where existing therapies have failed.
Industry Context
Actuate Therapeutics, Inc. operates in Oncology Drugs.
Key facts
Founded: 2015 · Headquarters: Fort Worth, Texas, US · Employees: 12 · Market cap: $33.5M (as of July 2026)